Company intelligence / Profile preview

Deuteria Pharmaceuticals

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

Deuteria Pharmaceuticals was a biopharmaceutical company specializing in the application of deuterium chemistry to enhance the properties of small molecule drugs. The company utilized a proprietary platform to selectively replace hydrogen atoms with deuterium, a stable isotope, to improve metabolic stability and reduce the formation of toxic metabolites. This approach aimed to create improved versions of existing drugs with better safety and dosing profiles. In late 2012, the company was acquired by Celgene Corporation, which sought to leverage Deuteria's technology across its internal development programs.

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Celgene

Beyond the preview

Go deeper on Deuteria Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deuteria Pharmaceuticals.

Explore the full profile